NEOGENOMICS, INC. (NASDAQ:NEO) Files An 8-K Results of Operations and Financial Condition

Item 2.02.

On April 26, 2017, NeoGenomics, Inc. (the Company) issued a press
release reporting its results for its first fiscal quarter of
2017.The press release is furnished herewith as Exhibit 99.1 and
is incorporated herein by reference.

This information shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, and it shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.

About NEOGENOMICS, INC. (NASDAQ:NEO)

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

NEOGENOMICS, INC. (NASDAQ:NEO) Recent Trading Information

NEOGENOMICS, INC. (NASDAQ:NEO) closed its last trading session down -1.04 at 7.47 with 332,158 shares trading hands.